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Abstract
Background: Trachoma, the leading infectious cause of blindness worldwide, is caused by conjunctival Chlamydia
trachomatis infection. Trachoma is diagnosed clinically by observation of conjunctival inflammation and/or scarring;
however, there is evidence that monitoring C. trachomatis infection may be required for elimination programmes.
There are many commercial and ‘in-house’ nucleic acid amplification tests for the detection of C. trachomatis DNA,
but the majority have not been validated for use with ocular swabs. This study evaluated a commercial assay, the
Fast-Track Vaginal swab kit, using conjunctival samples from trachoma-endemic areas. An objective, biostatistical-
based method for binary classification of continuous PCR data was developed, to limit potential user-bias in
diagnostic settings.
Methods: The Fast-Track Vaginal swab assay was run on 210 ocular swab samples from Guinea-Bissau and
Tanzania. Fit of individual amplification curves to exponential or sigmoid models, derivative and second derivative
of the curves and final fluorescence value were examined for utility in thresholding for determining positivity. The
results from the Fast-Track Vaginal swab assay were evaluated against a commercial test (Amplicor CT/NG) and a
non-commercial test (in-house droplet digital PCR), both of whose performance has previously been evaluated.
Results: Significant evidence of exponential amplification (R2 > 0.99) and final fluorescence > 0.15 were combined
for thresholding. This objective approach identified a population of positive samples, however there were a subset
of samples that amplified towards the end of the cycling protocol (at or later than 35 cycles), which were less
clearly defined. The Fast-Track Vaginal swab assay showed good sensitivity against the commercial (95.71) and non-
commercial (97.18) tests. Specificity was lower against both (90.00 and 96.55, respectively).
Conclusions: This study defined a simple, automated protocol for binary classification of continuous, real-time
qPCR data, for use in an end-point diagnostic test. This method identified a population of positive samples,
however, as with manual thresholding, a subset of samples that amplified towards the end of the cycling program
were less easily classified. When used with ocular swabs, the Fast-Track Vaginal swab assay had good sensitivity for
C. trachomatis detection, but lower specificity than the commercial and non-commercial assays it was evaluated
against, possibly leading to false positives.
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Background
Chlamydia trachomatis is the most common bacterial
sexually transmitted infection [1] and the leading infectious
cause of blindness worldwide [2]. Trachoma, conjunctival C.
trachomatis infection and subsequent disease, is responsible
for visual impairment or blindness in an estimated 2.2
million people [2]. Trachoma is targeted for elimination by
2020 [3], using a series of interventions known as SAFE [4]:
Surgery for trichiasis (inturned eyelashes), Antibiotics for
infection (community mass drug administration, MDA),
Facial cleanliness and Environmental improvement to reduce
transmission. Control programmes use clinical diagnosis of
trachoma for monitoring prevalence, chiefly signs of
trachomatous inflammation-follicular (TF) and trachomatous
inflammation-intense (TI). However, the correlation between
TF/TI and conjunctival C. trachomatis infection lessens as
prevalence declines [5, 6], suggesting tests for infection may
be necessary to accurately monitor trachoma dynamics,
particularly in low-endemicity and post-MDA settings [7].
Chlamydia trachomatis infection has historically been di-
agnosed through culture of the bacterium, antigen detection
and direct cytological examination [8]. Currently, nucleic
acid amplification tests (NAATs) are the gold standard for
C. trachomatis detection as they are more sensitive and
allow increased throughput. Many commercial and non-
commercial assays are available; however, the majority have
not been validated for use with ocular swabs. Incorporating
tests for C. trachomatis infection into trachoma control pro-
grammes, rather than relying on clinical diagnosis alone, has
the potential to reduce cost and increase success [9].
Positivity in NAATs based on real time qPCR assays,
such as Artus C. trachomatis Plus RG PCR Kit (Qiagen,
Hilden, Germany), is primarily based on samples
‘displaying an exponential trace’ [10] during thermal cyc-
ling, and there are a number of methods for binary
classification of samples into positives and negatives. It
is common for thresholds to be defined based on
manual inspection of traces, as well as by comparison to
positive and negative controls. Samples that demonstrate
exponential amplification before this manually defined
threshold are deemed positive. This inherently subjective
method introduces user-bias.
This study evaluated a commercial assay, the Fast-Track
Vaginal swab kit, for diagnosing C. trachomatis infection
from ocular swabs. Additionally, the study aimed to define
an objective method for binary classification of samples
using the raw PCR amplification curves, rather than
subjective thresholding by individual users.
Methods
Sample collection
Samples were collected from the upper tarsal conjunctiva
using a Dacron polyester-tipped swab (Hardwood Products
Company, Guilford, Maine). The swab was passed firmly
four times across the conjunctiva with a quarter turn
between each pass. All samples were kept on ice packs in the
field until transfer to -80 °C the same day for storage until
processing. Samples included were collected in Kilimanjaro
Region, northern Tanzania [11] (109) and Bijagos Islands,
Guinea-Bissau (101) as part of trachoma surveys.
DNA extraction and amplification
DNA was extracted from all swabs using the QIAmp
DNA mini kit (Qiagen, Crawley, UK). For sample process-
ing using the Fast-Track Diagnostic (FTD) Vaginal swab
kit (Fast-Track Diagnostics, Esch-sur-Alzette, Luxembourg),
10 μl extracted DNA was amplified in a total reaction vol-
ume of 25 μl. Positive and negative controls were included
in each run. Cycling conditions were as described in the
manufacturer’s instructions. Raw fluorescence data was
modeled to determine positivity as described below.
Chlamydia trachomatis was detected using the Amplicor
CT/NG kit (Roche Molecular Systems, Branchburg, NJ)
with previously described modifications [12]. Samples
whose absorbance values at 450 nm (A450) were ≥ 0.8 were
considered positive while samples less than 0.2 A450 were
considered negative. Samples for which the result was
equivocal (≥ 0.2, < 0.8) were tested again in duplicate. The
sample was only considered positive if the A450 of one of
the retests was ≥0.8. DNA amplification by droplet digital
PCR (ddPCR) was conducted as previously described [13].
A sample was considered positive if the 95% confidence
interval of C. trachomatis plasmid copies per μl did not
intersect zero.
Data analysis
The raw fluorescence data for the FTD Vaginal swab
PCR were used for all analyses. Data for Amplicor and
ddPCR were analysed as previously described [13, 14].
All analyses were performed using R version 3.3.2. Data
were fitted to exponential and sigmoid models using the
qpcR package. The mixtools package was used for
mixtures modelling. FTD Vaginal swab PCR was eval-
uated against the Amplicor CT/NG and ddPCR
assays, using the caret and psych packages to calcu-
late sensitivity, specificity, positive predictive value,
negative predictive value and Cohens kappa.
Results
Defining threshold for positivity
Two-hundred and ten upper tarsal conjunctival swabs
were tested for the presence of C. trachomatis infection
using the FTD Vaginal swab kit. Data from all 210
samples were used to determine an automated threshold
by which samples could be considered as either positive
or negative.
Raw amplification curves were fitted to exponential
and sigmoid models (four-parameter logistic regression)
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and evaluated using their respective R2-values, to test for
evidence of exponential amplification. Samples
evidenced by a clear exponential trace and final fluores-
cence intensity, including all positive controls, fitted
both models well. However, samples that had a final
fluorescence less than or equivalent to the negative
controls had variable R2-values, with many showing
strong fits for one or both models. This discrepancy was
demonstrated by poor correlation of fluorescence intensity
at cycle 40 and the model R2-values (exponential model;
correlation = 0.31, P-value = 0.0001 and sigmoid model;
correlation = 0.35, P-value < 0.0001). Good model fit in
samples that did not amplify was likely caused by instability
in low-level/background fluorescence, leading to fluctua-
tions that can be mistaken for amplification (Fig. 1). Using
model fit alone would classify these non-amplifying samples
as positive, dramatically reducing specificity. Similar results
were found with the derivative and second derivative of the
sigmoid models.
To overcome the limitations of only considering ‘clear’
exponential amplification, a minimum final fluorescence
component was incorporated into the method for
defining positive samples. The final fluorescence values
for each sample were modelled onto mixtures of two or
three normal distributions. Allowing three distributions
provided the optimum fit (log-likelihood = 474)
compared with two distributions (log-likelihood = 431).
Both models identified samples with a final fluorescence
above 0.15 units as a separate population. A mixture of
three distributions also highlighted a population of
samples with a final fluorescence between 0.05 and
0.15 units (Fig. 2).
Diagnostic evaluation of FTD Vaginal swab PCR
Finally, we conducted a diagnostic evaluation of the
FTD Vaginal swab kit against previously validated com-
mercial (Amplicor CT/NG [14]) and in-house (ddPCR
[13]) assays (Table 1), using a subset of 100 samples. For
diagnostic evaluation, two methods for identifying expo-
nential amplification were combined, sigmoid model R2-
value > 0.99 and final fluorescence > 0.15. Thirty of 100
samples were positive by Amplicor CT/NG; the FTD Va-
ginal swab kit and ddPCR correctly identified 27 of
these, respectively calling three and two additional posi-
tive results. Twenty-nine of 100 samples were positive
by ddPCR; the FTD Vaginal swab kit correctly identified
28 of these, additionally calling two further positive re-
sults. In-house ddPCR had greater sensitivity (97.14)
compared with Amplicor CT/NG than previously re-
ported [13].
The three Amplicor CT/NG-positive samples called as
negative by the FTD Vaginal swab kit and by ddPCR
were originally identified as equivocal samples before
retesting, per the Amplicor protocol. Two of three had
no positive droplets by ddPCR and a final fluorescence
by the FTD Vaginal swab kit of less than 0.01. The
remaining sample did not have enough positive droplets
to be reliably called as positive by ddPCR, but had a final
fluorescence above 0.1 by the FTD Vaginal swab kit.
Discussion
This study evaluated results for detection of C. tracho-
matis DNA from ocular swabs using the FTD Vaginal
swab kit, a commercial PCR assay validated for use with
urogenital samples, against previously validated
Fig. 1 Sigmoid models representative of variation in amplification. Raw fluorescence results from samples processed using the FTD Vaginal swab
kit. Sigmoid models representing: samples that did not amplify and do not fit a sigmoid model (a), samples that did not amplify but do fit a
sigmoid model (b), and samples that did amplify and do fit a sigmoid model (c)
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commercial and in-house assays. Automated methods
for determining thresholds for positivity from raw
amplification curves were also explored. A composite of
amplification curve fit and absolute level of amplification
was determined to be the best method for the identification
of positive results, although, as with setting a manual
threshold, there was some ambiguity assigning samples that
amplified at or later than 35 cycles. The FTD Vaginal swab
kit performed well against both comparator assays; however
specificity was notably lower versus Amplicor CT/NG.
Manual and inherently subjective binary classification of
continuous real time qPCR data is a significant problem, as
it creates unnecessary variability within and across assays.
Visual inspection of curves focuses on identifying clear
evidence of exponential/sigmoid amplification. This study
found that observation of exponential amplification could
not singularly define positivity, due to instability in low-level/
background fluorescence being mistaken for true amplifica-
tion. Including mixtures-model clusters defined using the
final fluorescence value greatly improved identification of
positive samples. For diagnostic evaluation, a sample was
deemed positive if: (i) the amplification curve was fit strongly
to a sigmoid model (R2-value > 0.99); and (ii) the sample
clustered within the right-most population of a mixtures-
model of three normal distributions (final fluores-
cence > 0.15). This objective method identified a
population of positive samples; however there was
some ambiguity in samples that appear to amplify late
in the reaction (at or later than 35 cycles), a problem
common to manual threshold setting and inspection.
A subset of samples, which formed the middle population
of the three distribution mixtures-model, described above,
showed varying levels of amplification using the FTD Va-
ginal swab assay, with final fluorescence values between
0.05 and 0.15. Of interest, the sample in this subset with
the highest final fluorescence was positive by Amplicor
CT/NG, after an initial equivocal result. As with Amplicor
CT/NG, samples that fit in this middle, less clear
population should, ideally, be retested.
The FTD Vaginal swab assay performed well against both
Amplicor CT/NG and ddPCR. Sensitivity was above 95% for
both, with three and one false negatives, respectively. One of
the false negatives, was a sample with a final fluorescence
over 0.1, which was initially equivocal by Amplicor CT/NG.
It is possible with retesting, as suggested above, this sample
might have been positive. Specificity was slightly lower
against both tests, notably down to 90% for Amplicor CT/
NG, with three and two false positives, respectively. Com-
pared with either assay, the specificity of FTD Vaginal swab
assay is below that of various alternative NAATs for C.
trachomatis [15].
Conclusion
Automated, unbiased classification of continuous real time
qPCR data into binary results, for diagnostic purposes, is
achievable using a simple set of biostatistical rules. The
method described allows objective classification of results
from qPCR, using the raw output from thermal cycling pro-
grams. FTD Vaginal swab PCR for use with ocular swabs has
lower specificity than both Amplicor CT/NG and ddPCR for
C. trachomatis detection, challenging its diagnostic utility
with this sample type.
Fig. 2 Mixtures models of final fluorescence values. Final fluorescence values, from samples processed using the FTD Vaginal swab kit, were
modelled onto mixtures of two (a) and three (b) normal distributions
Table 1 Diagnostic comparison of FTD vaginal swab PCR to
Amplicor CT/NG and in-house ddPCR
FTD vaginal swab PCR versus
Amplicor CT/NG
(Roche)
In-house ddPCR
(Bio-Rad QX100)
Sensitivity 95.71 (91.74–99.68) 97.18 (93.94–100.0)
Specificity 90.00 (84.12–95.88) 96.55 (92.97–100.0)
PPV 95.71 (91.74–99.68) 98.57 (96.24–100.0)
NPV 90.00 (84.12–95.88) 93.33 (88.44–98.22)
Cohens Kappa 0.86 0.93
Note: The 95% confidence intervals are shown in brackets
Abbreviations: ddPCR droplet digital PCR, NPV negative predictive value, PPV
positive predictive value
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Abbreviations
CT: Chlamydia trachomatis; ddPCR: Droplet digital PCR;
DNA: Deoxyribonucleic acid; FTD: Fast-Track Diagnostics; MDA: Mass drug
administration; NAAT: Nucleic acid amplification test; NG: Neisseria
gonorrheae; PCR: Polymerase chain reaction; qPCR: Quantitative PCR
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